|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Byers LA and Rudin CM: Small cell lung
cancer: Where do we go from here? Cancer. 121:664–672. 2015.
View Article : Google Scholar
|
|
3
|
Murray PJ, Allen JE, Biswas SK, Fisher EA,
Gilroy DW, Goerdt S, Gordon S, Hamilton JA, Ivashkiv LB, Lawrence
T, et al: Macrophage activation and polarization: Nomenclature and
experimental guidelines. Immunity. 41:14–20. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Cook J and Hagemann T: Tumour-associated
macrophages and cancer. Curr Opin Pharmacol. 13:595–601. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gordon S: Alternative activation of
macrophages. Nat Rev Immunol. 3:23–35. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Ruffell B and Coussens LM: Macrophages and
therapeutic resistance in cancer. Cancer Cell. 27:462–472. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Krausgruber T, Blazek K, Smallie T,
Alzabin S, Lockstone H, Sahgal N, Hussell T, Feldmann M and Udalova
IA: IRF5 promotes inflammatory macrophage polarization and TH1-TH17
responses. Nat Immunol. 12:231–238. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Allavena P, Sica A, Solinas G, Porta C and
Mantovani A: The inflammatory microenvironment in tumor
progression: The role of tumor-associated macrophages. Crit Rev
Oncol Hematol. 66:1–9. 2008. View Article : Google Scholar
|
|
9
|
Sica A and Mantovani A: Macrophage
plasticity and polarization: In vivo veritas. J Clin Invest.
122:787–795. 2012. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Santoni M, Massari F, Amantini C, Nabissi
M, Maines F, Burattini L, Berardi R, Santoni G, Montironi R,
Tortora G, et al: Emerging role of tumor-associated macrophages as
therapeutic targets in patients with metastatic renal cell
carcinoma. Cancer Immunol Immunother. 62:1757–1768. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Ruhrberg C and De Palma M: A double agent
in cancer: Deciphering macrophage roles in human tumors. Nat Med.
16:861–862. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Chen P and Bonaldo P: Role of macrophage
polarization in tumor angiogenesis and vessel normalization:
Implications for new anticancer therapies. Int Rev Cell Mol Biol.
301:1–35. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Ohri CM, Shikotra A, Green RH, Waller DA
and Bradding P: Macrophages within NSCLC tumour islets are
predominantly of a cytotoxic M1 phenotype associated with extended
survival. Eur Respir J. 33:118–126. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Zhang J, Cao J, Ma S, Dong R, Meng W, Ying
M, Weng Q, Chen Z, Ma J, Fang Q, et al: Tumor hypoxia enhances
non-small cell lung cancer metastasis by selectively promoting
macrophage M2 polarization through the activation of ERK signaling.
Oncotarget. 5:9664–9677. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Sun J, Mao Y, Zhang YQ, Guo YD, Mu CY, Fu
FQ and Zhang XG: Clinical significance of the induction of
macrophage differentiation by the costimulatory molecule B7-H3 in
human non-small cell lung cancer. Oncol Lett. 6:1253–1260.
2013.PubMed/NCBI
|
|
16
|
Domagala-Kulawik J: The role of the immune
system in non-small cell lung carcinoma and potential for
therapeutic intervention. Transl Lung Cancer Res. 4:177–190.
2015.PubMed/NCBI
|
|
17
|
Bartel DP: MicroRnAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Hammond SM: An overview of microRnAs. Adv
Drug Deliv Rev. 87:3–14. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Lan H, Lu H, Wang X and Jin H: MicroRNAs
as potential biomarkers in cancer: opportunities and challenges.
Biomed Res Int. 2015:1250942015. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Jasinski-Bergner S, Mandelboim O and
Seliger B: The role of microRNAs in the control of innate immune
response in cancer. J Natl Cancer Inst. 106:dju2572014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Park EK, Jung HS, Yang HI, Yoo MC, Kim C
and Kim KS: Optimized THP-1 differentiation is required for the
detection of responses to weak stimuli. Inflamm Res. 56:45–50.
2007. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Wang XF, Wang HS, Wang H, Zhang F, Wang
KF, Guo Q, Zhang G, Cai SH and Du J: The role of indoleamine
2,3-dioxygenase (IDO) in immune tolerance: Focus on macrophage
polarization of THP-1 cells. Cell Immunol. 289:42–48. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Movahedi K, Laoui D, Gysemans C, Baeten M,
Stangé G, Van den Bossche J, Mack M, Pipeleers D, In't Veld P, De
Baetselier P, et al: Different tumor microenvironments contain
functionally distinct subsets of macrophages derived from
Ly6C(high) monocytes. Cancer Res. 70:5728–5739. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Pucci F, Venneri MA, Biziato D, Nonis A,
Moi D, Sica A, Di Serio C, Naldini L and De Palma M: A
distinguishing gene signature shared by tumor-infiltrating
Tie2-expressing monocytes, blood 'resident' monocytes, and
embryonic macrophages suggests common functions and developmental
relationships. Blood. 114:901–914. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Rolny C, Mazzone M, Tugues S, Laoui D,
Johansson I, Coulon C, Squadrito ML, Segura I, Li X, Knevels E, et
al: HRG inhibits tumor growth and metastasis by inducing macrophage
polarization and vessel normalization through downregulation of
PlGF. Cancer Cell. 19:31–44. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Alam MM and O'Neill LA: MicroRNAs and the
resolution phase of inflammation in macrophages. Eur J Immunol.
41:2482–2485. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
He M, Xu Z, Ding T, Kuang DM and Zheng L:
MicroRnA-155 regulates inflammatory cytokine production in
tumor-associated macrophages via targeting C/EBPbeta. Cell Mol
Immunol. 6:343–352. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Ricote M, Li AC, Willson TM, Kelly CJ and
Glass CK: The peroxisome proliferator-activated receptor-gamma is a
negative regulator of macrophage activation. Nature. 391:79–82.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Bouhlel MA, Derudas B, Rigamonti E,
Dièvart R, Brozek J, Haulon S, Zawadzki C, Jude B, Torpier G, Marx
N, et al: PPARgamma activation primes human monocytes into
alternative M2 macrophages with anti-inflammatory properties. Cell
Metab. 6:137–143. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Huang JT, Welch JS, Ricote M, Binder CJ,
Willson TM, Kelly C, Witztum JL, Funk CD, Conrad D and Glass CK:
Interleukin-4-dependent production of PPAR-gamma ligands in
macrophages by 12/15-lipoxygenase. Nature. 400:378–382. 1999.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Berry A, Balard P, Coste A, Olagnier D,
Lagane C, Authier H, Benoit-Vical F, Lepert JC, Séguéla JP,
Magnaval JF, et al: IL-13 induces expression of CD36 in human
monocytes through PPARgamma activation. Eur J Immunol.
37:1642–1652. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Becker M, Müller CB, De Bastiani MA and
Klamt F: The prognostic impact of tumor-associated macrophages and
intratumoral apoptosis in non-small cell lung cancer. Histol
Histopathol. 29:21–31. 2014.
|
|
33
|
Xue Z, Wen J, Chu X and Xue X: A microRNA
gene signature for identification of lung cancer. Surg Oncol.
23:126–131. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Wali RK, Hensing TA, Ray DW, Dela Cruz M,
Tiwari AK, Radosevich A, Jepeal L, Fernando HC, Litle VR, Charlot
M, et al: Buccal microRnA dysregulation in lung field
carcinogenesis: gender-specific implications. Int J Oncol.
45:1209–1215. 2014.PubMed/NCBI
|
|
35
|
Piva R, Spandidos DA and Gambari R: From
microRnA functions to microRNA therapeutics: Novel targets and
novel drugs in breast cancer research and treatment (Review). Int J
Oncol. 43:985–994. 2013.PubMed/NCBI
|
|
36
|
Pan Y, Wang R, Zhang F, Chen Y, Lv Q, Long
G and Yang K: MicroRNA-130a inhibits cell proliferation, invasion
and migration in human breast cancer by targeting the RAB5A. Int J
Clin Exp Pathol. 8:384–393. 2015.PubMed/NCBI
|
|
37
|
Chen H, Li X, Li W and Zheng H: miR-130a
can predict response to temozolomide in patients with glioblastoma
multiforme, independently of O6-methylguanine-DnA
methyltransferase. J Transl Med. 13:692015. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Acunzo M, Visone R, Romano G, Veronese A,
Lovat F, Palmieri D, Bottoni A, Garofalo M, Gasparini P, Condorelli
G, et al: miR-130a targets MET and induces TRAIL-sensitivity in
NSCLC by downregulating miR-221 and 222. Oncogene. 31:634–642.
2012.
|
|
39
|
Maniecki MB, Etzerodt A, Ulhøi BP,
Steiniche T, Borre M, Dyrskjøt L, Orntoft TF, Moestrup SK and
Møller HJ: Tumor-promoting macrophages induce the expression of the
macrophage-specific receptor CD163 in malignant cells. Int J
Cancer. 131:2320–2331. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
He KF, Zhang L, Huang CF, Ma SR, Wang YF,
Wang WM, Zhao ZL, Liu B, Zhao YF, Zhang WF, et al: CD163
tumor-associated macrophages correlated with poor prognosis and
cancer stem cells in oral squamous cell carcinoma. Biomed Res Int.
2014:8386322014. View Article : Google Scholar
|
|
41
|
De Palma M and Lewis CE: Macrophage
regulation of tumor responses to anticancer therapies. Cancer Cell.
23:277–286. 2013. View Article : Google Scholar : PubMed/NCBI
|
